Highlights

  • Nyrada (ASX:NYR) commenced patient dosing in its Phase IIa PROTECT-MI trial evaluating Xolatryp in heart attack patients.
  • The trial is assessing whether Xolatryp can reduce damage caused by reperfusion injury.
  • PROTECT-MI is designed to enrol approximately 200 patients across Australian hospitals.
  • Clinical results and future regulatory progress remain key milestones for the program.

Nyrada (ASX:NYR) has progressed its lead cardiovascular drug candidate Xolatryp into human testing after dosing the first patient in its Phase IIa PROTECT-MI trial.

The study represents the first clinical evaluation of the company’s approach to reducing heart muscle damage following a major heart attack.

While the milestone advances the program into the clinic, the trial remains an early-stage evaluation focused primarily on safety and initial efficacy signals.

What Happened?

On 6 July 2026, Nyrada announced that the first patient had been dosed in PROTECT-MI, a Phase IIa clinical trial evaluating Xolatryp (NYR-BI03) in patients experiencing ST-elevation myocardial infarction (STEMI).

STEMI is a severe form of heart attack where emergency treatment involves primary percutaneous coronary intervention (PCI) to restore blood flow.

The trial follows earlier human research ethics approvals and site activation activities across Australia.

Recruitment locations include Nepean Hospital in New South Wales and Sir Charles Gairdner Hospital in Western Australia, with additional sites progressing through approvals.

Why It Matters

Nyrada is targeting reperfusion injury, a process where restoring blood flow after a blocked artery can trigger additional cellular damage.

During reperfusion, excessive calcium entry into heart cells can affect mitochondrial function and contribute to further injury.

Xolatryp is designed to inhibit TRPC 3/6/7 ion channels, reducing pathological calcium influx and potentially protecting heart muscle during the recovery period following a heart attack.

Currently, there are no approved therapies specifically designed to prevent reperfusion injury.

If successful, Xolatryp could address an unmet clinical need associated with long-term heart failure risk following myocardial infarction.

The Numbers

PROTECT-MI is a randomised, double-blind, placebo-controlled Phase IIa study.

The trial is designed to enrol approximately 200 patients, with participants randomised on a 1:1 basis between Xolatryp and placebo.

The study is expected to involve up to 10 hospitals across Australia.

Patients receive Xolatryp through an intravenous infusion at 3 mg/kg over six hours.

Each participant is monitored for 30 days.

The primary objective is safety and tolerability, including cardiac safety in acute heart attack patients.

Secondary and exploratory measures include infarct size assessed through cardiac magnetic resonance imaging, serum troponin I levels, arrhythmias and patient-reported outcomes.

Nyrada reported approximately A$8.39 million in cash as at 30 June 2026, with quarterly cash outflow of around A$1.66 million.

The Bigger Picture

Nyrada’s cardioprotection program is based on TRPC channel biology, supported by intellectual property development and regulatory planning.

The company has secured US Patent protection for the program and intends to engage with the United States Food and Drug Administration (FDA) through pre-investigational new drug discussions and a potential investigational new drug application.

Reperfusion injury represents a large medical challenge, but the development pathway is also difficult, with previous candidates failing to demonstrate meaningful clinical benefits despite promising early data.

PROTECT-MI is designed as an early-stage study to establish safety and identify potential signals rather than provide definitive proof of clinical effectiveness.

The Bull Case

The positive case for Nyrada (ASX:NYR) is based on developing a treatment for a defined cardiovascular problem with no approved pharmacological solution.

Xolatryp has a mechanism designed specifically around reducing reperfusion-related heart damage.

Successful safety results and early efficacy signals could support progression into larger clinical studies and strengthen regulatory discussions.

The company’s focus on a first-in-class cardioprotection approach provides potential differentiation within cardiovascular drug development.

Risks Investors Should Understand

Nyrada (ASX:NYR)’s Business faces risks including clinical trial uncertainty, funding requirements, recruitment challenges and regulatory delays.

Reperfusion injury has historically been difficult to treat, and positive preclinical findings may not translate into meaningful patient outcomes.

As a Phase IIa safety-focused study, PROTECT-MI is not designed to provide definitive evidence of clinical benefit.

Recruitment may also prove challenging because STEMI treatment occurs in emergency settings with limited time for patient enrolment.

The company remains pre-revenue with a limited cash balance relative to future clinical development costs, creating potential funding and dilution risks.

What Comes Next?

The next milestones include continued patient recruitment, activation of additional trial sites and progress towards the planned 200-patient enrolment target.

Nyrada expects the final patient dosing timeline to extend towards mid-2027, with topline results expected after completion of the 30-day follow-up period.

Investors will also monitor US regulatory engagement and funding requirements as the program progresses.

Conclusion

Nyrada (ASX:NYR) has reached an important milestone by moving Xolatryp into human testing through the PROTECT-MI Phase IIa trial.

The program targets a significant unmet need in cardiovascular medicine by attempting to reduce reperfusion injury following heart attacks.

However, the trial represents the beginning of clinical validation rather than confirmation of effectiveness. Future value will depend on patient outcomes, regulatory progress, funding capacity and the ability to demonstrate meaningful clinical benefit.